Antonio Carrascosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Antonio Carrascosa has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Diego Yeste
AEP Asociación Española de Pediatría, Madrid, Spain
17 shared publications - Neus Potau
Hormonal Laboratory, Hospital Materno-Infantil Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain
11 shared publications - E. Vicens-Calvet
Hospital Universitario Materno-Infantil Vall d'Hebron, Barcelona, Spain
10 shared publications - Laura Audí
Growth Hormone and Related Substances Utilization Advisory Council, Catalan Health Service, Barcelona, Spain
10 shared publications - Mónica Fernández-Cancio
Growth and Development Group, Vall d’Hebron Institut de Recerca (VHIR)—Pediatric Endocrinology Section, Hospital Universitari Vall d’Hebron (HUVH), 08035 Barcelona, Spain
7 shared publications M Albisu
Hospital Universitari Materno-Infantil Vall d'Hebron, Barcelona, Spain
6 shared publications
Latest Publications
- Open Access
- 1 September 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 89 (3) , 137-143
Índice de masa corporal e índice de masa triponderal de 1.453 niños no obesos ni malnutridos de la generación del milenio. Estudio longitudinal de Barcelona
- 1 September 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 89 (3) , 137-143
Open AccessÍndice de masa corporal e índice de masa triponderal de 1.453 niños no obesos ni malnutridos de la generación del milenio. Estudio longitudinal de Barcelona
- Open Access
- 1 September 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 89 (3) , 137-143
Body mass index and tri-ponderal mass index of 1,453 healthy non-obese, non-undernourished millennial children. The Barcelona longitudinal growth study
- 1 September 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 89 (3) , 137-143
Open AccessBody mass index and tri-ponderal mass index of 1,453 healthy non-obese, non-undernourished millennial children. The Barcelona longitudinal growth study
- Open Access
- 1 September 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 89 (3) , 144-152
Crecimiento puberal de 1.453 niños sanos según la edad de inicio de la pubertad. Estudio longitudinal de Barcelona
- 1 September 2018
- Published by Elsevier in Anales de Pediatría
- Vol. 89 (3) , 144-152
Open AccessCrecimiento puberal de 1.453 niños sanos según la edad de inicio de la pubertad. Estudio longitudinal de Barcelona
- Open Access
- 1 September 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 89 (3) , 144-152
Pubertal growth of 1,453 healthy children according to age at pubertal growth spurt onset. The Barcelona longitudinal growth study
- 1 September 2018
- Published by Elsevier in Anales de Pediatría (English Edition)
- Vol. 89 (3) , 144-152
Open AccessPubertal growth of 1,453 healthy children according to age at pubertal growth spurt onset. The Barcelona longitudinal growth study
- 1 June 2018
- Published by Elsevier in Endocrinología, Diabetes y Nutrición (English Ed.)
- Vol. 65 (6) , 311-313
Barcelona Longitudinal Growth Study 1995–2017
- 1 June 2018
- Published by Elsevier in Endocrinología, Diabetes y Nutrición (English Ed.)
- Vol. 65 (6) , 311-313
Barcelona Longitudinal Growth Study 1995–2017
- 1 May 2014
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 61 (5) , 229-233
Aceleración secular de crecimiento en España. Estudios Españoles de Crecimiento 2010. Población autóctona y población inmigrante
- 1 May 2014
- Published by Elsevier in Endocrinología y Nutrición
- Vol. 61 (5) , 229-233
Aceleración secular de crecimiento en España. Estudios Españoles de Crecimiento 2010. Población autóctona y población inmigrante
- 28 March 2013
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 79 (3) , 145-156
Height Gain at Adult-Height Age in 184 Short Patients Treated with Growth Hormone from Prepubertal Age to Near Adult-Height Age is Not Related to GH Secretory Status at GH Therapy Onset
Background: GH release after stimuli classifies short children as severe idiopathic isolated GH deficiency (IIGHD), mild IIGHD, dissociated GH release (DGHR) and normal GH release (NGHR) and anthropometric birth data as adequate for gestational age (AGA) or small for gestational age (SGA). GH release after stimuli classifies AGA patients as IIGHD or as idiopathic short stature (ISS). Aim: To compare height gain induced by GH therapy (31.8 ± 3.5 µg/kg/day, 7.7 ± 1.6 years) started at prepubertal age and stopped at near adult-height age. Methods: A retrospective longitudinal multicenter study including 184 short patients classified as severe IIGHD n = 25, mild IIGHD n = 75, DGHR n = 55 and NGHR n = 29; or as IIGHD n = 78, ISS n = 57 and SGA n = 49. Height gain was evaluated throughout GH therapy and at adult-height age. Results: Height-SDS gain at adult-height age was similar among severe IIGHD (1.8 ± 0.8 SDS), mild IIGHD (1.6 ± 0.6 SDS), DGHR (1.7 ± 0.7 SDS) and NGHR (1.6 ± 0.7 SDS), or among IIGHD (1.7 ± 0.7 SDS), ISS (1.7 ± 0.6 SDS) and SGA (1.6 ± 0.8 SD). Conclusion: GH-release stimuli are of little help for deciding on GH therapy in the clinical management of prepubertal children with IIGHD, ISS or SGA.
- 28 March 2013
- Published by S. Karger AG in Hormone Research in Paediatrics
- Vol. 79 (3) , 145-156
Height Gain at Adult-Height Age in 184 Short Patients Treated with Growth Hormone from Prepubertal Age to Near Adult-Height Age is Not Related to GH Secretory Status at GH Therapy Onset
Background: GH release after stimuli classifies short children as severe idiopathic isolated GH deficiency (IIGHD), mild IIGHD, dissociated GH release (DGHR) and normal GH release (NGHR) and anthropometric birth data as adequate for gestational age (AGA) or small for gestational age (SGA). GH release after stimuli classifies AGA patients as IIGHD or as idiopathic short stature (ISS). Aim: To compare height gain induced by GH therapy (31.8 ± 3.5 µg/kg/day, 7.7 ± 1.6 years) started at prepubertal age and stopped at near adult-height age. Methods: A retrospective longitudinal multicenter study including 184 short patients classified as severe IIGHD n = 25, mild IIGHD n = 75, DGHR n = 55 and NGHR n = 29; or as IIGHD n = 78, ISS n = 57 and SGA n = 49. Height gain was evaluated throughout GH therapy and at adult-height age. Results: Height-SDS gain at adult-height age was similar among severe IIGHD (1.8 ± 0.8 SDS), mild IIGHD (1.6 ± 0.6 SDS), DGHR (1.7 ± 0.7 SDS) and NGHR (1.6 ± 0.7 SDS), or among IIGHD (1.7 ± 0.7 SDS), ISS (1.7 ± 0.6 SDS) and SGA (1.6 ± 0.8 SD). Conclusion: GH-release stimuli are of little help for deciding on GH therapy in the clinical management of prepubertal children with IIGHD, ISS or SGA.
- 1 March 2013
- Vol. 38 (1) , 1-16
Growth hormone deficiency: an update.
Growth hormone (GH) deficiency (GHD) in humans manifests differently according to the individual developmental stage (early after birth, during childhood, at puberty or in adulthood), the cause or mechanism (genetic, acquired or idiopathic), deficiency intensity and whether it is the only pituitary-affected hormone or is combined with that of other pituitary hormones or forms part of a complex syndrome. Growing knowledge of the genetic basis of GH deficiency continues to provide us with useful information to further characterise mutation types and mechanisms for previously described and new candidate genes. Despite these advances, a high proportion of GH deficiencies with no recognisable acquired basis continue to be labelled as idiopathic, although less frequently when they are congenital and/or familial. The clinical and biochemical diagnoses continue to be a conundrum despite efforts to harmonise biochemical assays for GH and IGF-1 analysis, probably because the diagnosis based on the so-called GH secretion stimulation tests will prove to be of limited usefulness for predicting therapy indications.
- 1 March 2013
- Vol. 38 (1) , 1-16
Growth hormone deficiency: an update.
Growth hormone (GH) deficiency (GHD) in humans manifests differently according to the individual developmental stage (early after birth, during childhood, at puberty or in adulthood), the cause or mechanism (genetic, acquired or idiopathic), deficiency intensity and whether it is the only pituitary-affected hormone or is combined with that of other pituitary hormones or forms part of a complex syndrome. Growing knowledge of the genetic basis of GH deficiency continues to provide us with useful information to further characterise mutation types and mechanisms for previously described and new candidate genes. Despite these advances, a high proportion of GH deficiencies with no recognisable acquired basis continue to be labelled as idiopathic, although less frequently when they are congenital and/or familial. The clinical and biochemical diagnoses continue to be a conundrum despite efforts to harmonise biochemical assays for GH and IGF-1 analysis, probably because the diagnosis based on the so-called GH secretion stimulation tests will prove to be of limited usefulness for predicting therapy indications.
- 1 August 2012
- Published by Elsevier in Anales de Pediatría
- Vol. 77 (2) , 71-74
El manejo de la obesidad en la infancia y adolescencia: de la dieta a la cirugía
- 1 August 2012
- Published by Elsevier in Anales de Pediatría
- Vol. 77 (2) , 71-74
El manejo de la obesidad en la infancia y adolescencia: de la dieta a la cirugía